Tech Company Financing Transactions
Elicio Therapeutics Funding Round
Elicio Therapeutics closed a $33 million Series B venture capital round on 10/3/2019. Investors included Clal Biotechnology Industries, EFung Capital and Livzon Mabpharm.
Transaction Overview
Company Name
Announced On
10/3/2019
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance Elicio's pipeline of novel lymph node targeted immuno-therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 1400 West 14303
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Elicio, based in Cambridge MA, is committed to transforming the lives of patients and their families by re-engineering the body's immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Connelly
Chief Medical Officer
Christopher Haqq
VP - Bus. Development
Charles Chase
VP - Bus. Development
Annette Matthies
VP - Operations
Michael DiVecchia
VP - Operations
Esther Welkowsky
VP - R & D
Peter DeMuth
VP - Regulatory Affairs
Nicole Hsu
Browse more venture capital transactions:
Prev: 10/3/2019: The Whole Coffee Company venture capital transaction
Next: 10/3/2019: Geneoscopy venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. All VC database entries reported here are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs